NO20073719L - Kjemiske forbindelser - Google Patents
Kjemiske forbindelserInfo
- Publication number
- NO20073719L NO20073719L NO20073719A NO20073719A NO20073719L NO 20073719 L NO20073719 L NO 20073719L NO 20073719 A NO20073719 A NO 20073719A NO 20073719 A NO20073719 A NO 20073719A NO 20073719 L NO20073719 L NO 20073719L
- Authority
- NO
- Norway
- Prior art keywords
- chemical compounds
- relates
- useful
- cancer
- chemical connections
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64682005P | 2005-01-25 | 2005-01-25 | |
| PCT/GB2006/000223 WO2006079791A1 (en) | 2005-01-25 | 2006-01-24 | Chemical compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20073719L true NO20073719L (no) | 2007-08-22 |
Family
ID=36588681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20073719A NO20073719L (no) | 2005-01-25 | 2007-07-18 | Kjemiske forbindelser |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20080146570A1 (pt) |
| EP (1) | EP1924573A1 (pt) |
| JP (1) | JP2008528473A (pt) |
| KR (1) | KR20070107061A (pt) |
| CN (1) | CN101146789A (pt) |
| AU (1) | AU2006208834A1 (pt) |
| BR (1) | BRPI0606930A2 (pt) |
| CA (1) | CA2594708A1 (pt) |
| IL (1) | IL184673A0 (pt) |
| MX (1) | MX2007008924A (pt) |
| NO (1) | NO20073719L (pt) |
| WO (1) | WO2006079791A1 (pt) |
| ZA (1) | ZA200706497B (pt) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2009000448A1 (es) * | 2008-02-29 | 2009-11-27 | Genentech Inc | Compuestos derivados de 3-sulfonilamino-n-(1h-pirazolo-[3,4-b]piridin-5il)benzamida; procesos de preparacion; compuestos intermediarios; composicion farmaceutica; y uso para el tratamiento del cancer, tal como sarcoma, carcinoma, adenoma, entre otros. |
| MX2010009410A (es) * | 2008-02-29 | 2010-11-30 | Array Biopharma Inc | Compuestos del inhibidor de raf y métodos de uso de los mismos. |
| JP2011513329A (ja) * | 2008-02-29 | 2011-04-28 | アレイ バイオファーマ、インコーポレイテッド | ＲＡＦ阻害化合物として使用されるイミダゾ［４，５−ｂ］ピリジン誘導体 |
| US20110003859A1 (en) * | 2008-02-29 | 2011-01-06 | Array Biopharma Inc. | N- (6-aminopyridin-3-yl) -3- (sulfonamido) benzamide derivatives as b-raf inhibitors for the treatment of cancer |
| JP6067226B2 (ja) | 2009-03-13 | 2017-01-25 | アジオス ファーマシューティカルズ， インコーポレイテッド | 細胞増殖関連疾患のための方法および組成物 |
| NZ596123A (en) * | 2009-05-19 | 2014-08-29 | Dow Agrosciences Llc | Compounds and methods for controlling fungi |
| CR20170071A (es) | 2009-06-29 | 2017-03-28 | Agios Pharmaceuticals Inc | Compuestos terapeuticos y composiciones |
| CN102548987B (zh) * | 2009-07-14 | 2014-04-16 | 江苏迈度药物研发有限公司 | 作为激酶抑制剂的氟取代化合物及其使用方法 |
| WO2011050210A1 (en) | 2009-10-21 | 2011-04-28 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| US20140323519A1 (en) * | 2011-04-26 | 2014-10-30 | Merck Sharp & Dohme Corp. | Heterocyclic compounds as b-raf inhibitors for treatment of cancer |
| ME03074B (me) | 2011-05-03 | 2019-01-20 | Agios Pharmaceuticals Inc | Akтivatori piruvat kinaze za upotrebu u terapiji |
| CN102827073A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| CN102827170A (zh) | 2011-06-17 | 2012-12-19 | 安吉奥斯医药品有限公司 | 治疗活性组合物和它们的使用方法 |
| KR101893112B1 (ko) | 2012-01-06 | 2018-08-30 | 아지오스 파마슈티컬스 아이엔씨. | 치료학적으로 활성인 화합물 및 이의 이용 방법 |
| WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| CN102887860B (zh) * | 2012-09-29 | 2015-07-01 | 上海泰坦科技有限公司 | 4-氯-6-三氟甲基嘧啶类化合物的制备方法 |
| WO2014062511A1 (en) | 2012-10-15 | 2014-04-24 | Agios Pharmaceuticals, Inc. | Therapeutic compounds and compositions |
| WO2015003360A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| PE20160744A1 (es) | 2013-07-11 | 2016-08-01 | Agios Pharmaceuticals Inc | Compuestos de n,6-bis(aril o heteroaril)-1,3,5-triazin-2,4-diamina como inhibidores de idh2 mutantes para el tratamiento de cancer |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| CA2917671A1 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | 2,4-or 4,6-diaminopyrimidine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US20150031627A1 (en) | 2013-07-25 | 2015-01-29 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| WO2015041533A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | Rock in combination with mapk-pathway |
| WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
| PH12021551647A1 (en) | 2014-03-14 | 2022-06-06 | Agios Pharmaceuticals Inc | Pharmaceutical compositions of therapeutically active compounds |
| MA44392B1 (fr) | 2015-06-11 | 2023-10-31 | Agios Pharmaceuticals Inc | Procédés d'utilisation d'activateurs de la pyruvate kinase |
| KR20250126877A (ko) | 2015-10-15 | 2025-08-25 | 르 라보레또레 쎄르비에르 | 악성 종양의 치료를 위한 조합물 요법 |
| ES2897959T3 (es) | 2015-10-15 | 2022-03-03 | Servier Lab | Terapia de combinación para tratar neoplasias malignas |
| US10980788B2 (en) | 2018-06-08 | 2021-04-20 | Agios Pharmaceuticals, Inc. | Therapy for treating malignancies |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CA3159348A1 (en) | 2019-11-08 | 2021-05-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| CN118251386A (zh) | 2021-11-12 | 2024-06-25 | 优迈特株式会社 | 含氟嘧啶化合物、有害菌类防除剂和含氟嘧啶化合物的制造方法 |
| WO2025073765A1 (en) | 2023-10-03 | 2025-04-10 | Institut National de la Santé et de la Recherche Médicale | Methods of prognosis and treatment of patients suffering from melanoma |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002047690A1 (en) * | 2000-12-12 | 2002-06-20 | Cytovia, Inc. | Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| US7071216B2 (en) * | 2002-03-29 | 2006-07-04 | Chiron Corporation | Substituted benz-azoles and methods of their use as inhibitors of Raf kinase |
-
2006
- 2006-01-24 CA CA002594708A patent/CA2594708A1/en not_active Abandoned
- 2006-01-24 MX MX2007008924A patent/MX2007008924A/es not_active Application Discontinuation
- 2006-01-24 US US11/814,246 patent/US20080146570A1/en not_active Abandoned
- 2006-01-24 KR KR1020077019306A patent/KR20070107061A/ko not_active Withdrawn
- 2006-01-24 EP EP06701019A patent/EP1924573A1/en not_active Withdrawn
- 2006-01-24 WO PCT/GB2006/000223 patent/WO2006079791A1/en not_active Ceased
- 2006-01-24 CN CNA2006800093601A patent/CN101146789A/zh active Pending
- 2006-01-24 JP JP2007551750A patent/JP2008528473A/ja active Pending
- 2006-01-24 AU AU2006208834A patent/AU2006208834A1/en not_active Abandoned
- 2006-01-24 BR BRPI0606930-4A patent/BRPI0606930A2/pt not_active IP Right Cessation
-
2007
- 2007-07-17 IL IL184673A patent/IL184673A0/en unknown
- 2007-07-18 NO NO20073719A patent/NO20073719L/no not_active Application Discontinuation
- 2007-07-24 ZA ZA200706497A patent/ZA200706497B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007008924A (es) | 2007-08-21 |
| IL184673A0 (en) | 2007-12-03 |
| KR20070107061A (ko) | 2007-11-06 |
| EP1924573A1 (en) | 2008-05-28 |
| BRPI0606930A2 (pt) | 2009-12-01 |
| CA2594708A1 (en) | 2006-08-03 |
| AU2006208834A1 (en) | 2006-08-03 |
| CN101146789A (zh) | 2008-03-19 |
| US20080146570A1 (en) | 2008-06-19 |
| WO2006079791A1 (en) | 2006-08-03 |
| ZA200706497B (en) | 2008-08-27 |
| JP2008528473A (ja) | 2008-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20073719L (no) | Kjemiske forbindelser | |
| NO20082709L (no) | Kjemiske forbindelser | |
| NO20070199L (no) | Substituerte kinazoloner som anti-kreftmidler | |
| NO20072784L (no) | Pyridenkarboksamidderivater for anvendelse som anticancer midler | |
| NO20071776L (no) | Kinoksaliner som B RAF inhibitorer. | |
| NO20091683L (no) | Kjemiske forbindelser | |
| NO20070566L (no) | Azin-karboksamider som antikreftmiddel | |
| NO20071246L (no) | Kinazolinonderivater og deres anvendelse som B-RAF-inhibitorer. | |
| NO20084202L (no) | 4-anilinoquinolin-3-carboksamider som CSF-1R kinase inhibitorer | |
| NO20071245L (no) | Kinazolinonderivater og deres anvendelse som b-RAF-inhibitorer. | |
| TW200635899A (en) | Chemical compounds | |
| WO2007113558A3 (en) | Quinazolinone derivatives having b-raf inhibitory activity | |
| NO20070655L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft | |
| NO20081729L (no) | Nye diazaspiroalkaner og deres anvendelse for behandling av CCR8-medierte sykdommer | |
| NO20092342L (no) | Azaspiroderivativater | |
| NO20082690L (no) | Kjemiske forbindelser | |
| NO20082124L (no) | Bifenyloksyeddiksyrederivater for behandling av respiratorisk sykdom | |
| NO20076675L (no) | Aminopiperidinquinoliner og deres azaisosteriske analoger med antibakteriell aktivitet | |
| NO20070656L (no) | 2,4,6-Trisubstituerte pyrimidiner som fosfotidylinositol-(PI)-3-kinaseinhibitorer og disses anvendelse ved behandling av kreft | |
| NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
| TW200736234A (en) | Chemical compounds | |
| NO20061743L (no) | Kinazolinderivater | |
| NO20085176L (no) | Fenyl substituerte heteroaryl-derivater og andvendelse som anti-tumor agenter | |
| NO20072548L (no) | Xantinderivater med HM74A reseptoraktivitet | |
| NO20074856L (no) | Transkarotenoide, deres syntese, formulering og anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |